Dade Behring Marburg Gmbh

Novartis Ag

Chiron Behring Gmbh & Co.

Michael Br&ouml;ker

Bernd Meyhack

Horst Domdey

Leander Lauffer

Michael Noah

Michael Mach

Klaus-Dieter Hungerer

Bernd-Ulrich Von Specht

Bernhard Knapp

Heidi Meyer

Structural phosphoprotein (pp28) of human cytomegalovirus (HCMV), the preparation and use thereof

The present invention relates to a hybrid protein comprising the,outer membrane protein I (OprI) which is fused with its amino terminal end to the carboxy-terminal end of a carboxy-terminal portion of the,outer membrane protein F (OprF), as well as to monoclonal or polyclonal antibodies against this hybrid protein. Both, the hybrid protein and the antibodies directed to the hybrid protein confer protection against an infection by,to laboratory animals or man.

Immunogenic hybrid protein OprF-Oprl derived from Pseudomonas aeruginosa membrane proteins

The invention pertains to the field of recombinant DNA technology and concerns a method for the production of a protein heterologous to yeast in a homogenous form with the aid of,strain HT393 or a derivative thereof carrying a hybrid vector containing the genes for said protein.

Process for the production of proteins

Recombinant yeast expression vectors with the features indicated in the patent claims are described. These recombinant yeast expression vectors can be used for the preparation of HBeAg in yeast host organisms. Appropriate expression systems, transformed host organisms, diagnostic aids and medicinal agents are additionally described.

Recombinant proteins with the immunoreactivity of hepatitis B virus e antigen (HBeAg), a process for the preparation thereof and the use thereof in immunoassays and vaccines

Growing community of inventors

Marburg, Germany

Michael Bröker

Growing community of inventors

Marburg, Germany

Michael Br&ouml;ker

Michael Bröker